Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Cost effectiveness of treatments for wet age-related macular degeneration.

Mitchell P, Annemans L, White R, Gallagher M, Thomas S.

Pharmacoeconomics. 2011 Feb;29(2):107-31. doi: 10.2165/11585520-000000000-00000. Review.

PMID:
21244102
2.

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.

Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A.

Health Technol Assess. 2008 May;12(16):iii-iv, ix-201. Review.

4.

Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.

Hernández-Pastor LJ, Ortega A, García-Layana A, Giráldez J.

Graefes Arch Clin Exp Ophthalmol. 2010 Apr;248(4):467-76. doi: 10.1007/s00417-009-1156-9. Epub 2009 Aug 11.

PMID:
19669678
5.

Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece.

Athanasakis K, Fragoulakis V, Tsiantou V, Masaoutis P, Maniadakis N, Kyriopoulos J.

Clin Ther. 2012 Feb;34(2):446-56. doi: 10.1016/j.clinthera.2012.01.005. Epub 2012 Jan 30.

PMID:
22289279
6.

Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK.

Wolowacz SE, Roskell N, Kelly S, Maciver FM, Brand CS.

Pharmacoeconomics. 2007;25(10):863-79.

PMID:
17887807
7.

A cost-effectiveness analysis of three treatments for age-related macular degeneration.

Gower EW, Cassard SD, Bass EB, Schein OD, Bressler NM.

Retina. 2010 Feb;30(2):212-21. doi: 10.1097/IAE.0b013e3181babd8e.

PMID:
19940805
8.

Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.

Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J.

Clin Ther. 2008 Dec;30(12):2436-51. doi: 10.1016/j.clinthera.2008.12.025.

PMID:
19167602
9.

A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration.

Brown GC, Brown MM, Brown HC, Kindermann S, Sharma S.

Ophthalmology. 2007 Jun;114(6):1170-8. Epub 2007 Feb 23.

PMID:
17320964
10.

Pharmacological treatments for neovascular age-related macular degeneration: can mixed treatment comparison meta-analysis be useful?

Virgili G, Novielli N, Menchini F, Murro V, Giacomelli G.

Curr Drug Targets. 2011 Feb;12(2):212-20. Review.

PMID:
20887240
11.

Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration.

Vedula SS, Krzystolik MG.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005139. doi: 10.1002/14651858.CD005139.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;8:CD005139.

12.

A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration.

Karnon J, Czoski-Murray C, Smith K, Brand C, Chakravarthy U, Davis S, Bansback N, Beverley C, Bird A, Harding S, Chisholm I, Yang YC.

Health Technol Assess. 2008 Jun;12(27):iii-iv, ix-124.

13.

Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review.

Takeda AL, Colquitt J, Clegg AJ, Jones J.

Br J Ophthalmol. 2007 Sep;91(9):1177-82. Epub 2007 May 2. Review.

14.

Cost and effectiveness of therapy for wet age-related macular degeneration in routine clinical practice.

Studnička J, Říhová B, Rencová E, Rozsíval P, Dubská Z, Chrapek O, Kolář P, Kandrnal V, Demlová R, Pitrová Š, Řehák J.

Ophthalmologica. 2013;230(1):34-42. doi: 10.1159/000350802. Epub 2013 Jun 7.

PMID:
23751929
15.
16.

Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.

Becerra EM, Morescalchi F, Gandolfo F, Danzi P, Nascimbeni G, Arcidiacono B, Semeraro F.

Curr Drug Targets. 2011 Feb;12(2):149-72. Review.

PMID:
20887246
17.

Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.

Kourlas H, Abrams P.

Clin Ther. 2007 Sep;29(9):1850-61. Review.

PMID:
18035187
18.

Patient characteristics and treatment of neovascular age-related macular degeneration in France: the LUEUR1 observational study.

Cohen SY, Souied EH, Weber M, Dupeyron G, de Pouvourville G, Lievre M, Ponthieux A.

Graefes Arch Clin Exp Ophthalmol. 2011 Apr;249(4):521-7. doi: 10.1007/s00417-010-1553-0. Epub 2010 Nov 6.

PMID:
21057805
19.

The burden of age-related macular degeneration.

Schmier JK, Jones ML, Halpern MT.

Pharmacoeconomics. 2006;24(4):319-34. Review.

PMID:
16605279
20.

[Cost-effectiveness of ranibizumab, photodynamic therapy and pegaptanib sodium in the treatment of neovascular age-related macular degeneration in Japanese].

Yanagi Y, Aihara Y, Fukuda T, Hashimoto H.

Nippon Ganka Gakkai Zasshi. 2011 Sep;115(9):825-31. Japanese.

PMID:
22073599
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk